RBC Capital analyst Gregory Renza maintained a Buy rating on Morphic Holding (MORF – Research Report) yesterday and set a price target of $70.00. The company’s shares closed yesterday at $27.98.
According to TipRanks, Renza is a 5-star analyst with an average return of 17.2% and a 45.27% success rate. Renza covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Alpine Immune Sciences, and ADC Therapeutics.
Morphic Holding has an analyst consensus of Strong Buy, with a price target consensus of $62.00, which is a 121.59% upside from current levels. In a report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $64.00 price target.
The company has a one-year high of $63.08 and a one-year low of $19.35. Currently, Morphic Holding has an average volume of 497.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Morphic Holding (MORF) Company Description:
Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.
Read More on MORF:
- Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
- Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
- Morphic appoints Cooper as Chief Medical Officer
- Morphic Holding Unveils Updated Corporate Presentation
- Morphic price target lowered to $66 from $68 at Canaccord
